Search Results

Home → Flash News → ep 175 with jens carlsson clip 3 AI is changing how we think about structure, function GPCR Podcast AI is changing how we think about structure, function, and discovery — but Jens Carlsson A good model doesn’t just match published structures; it forecasts new biology, new ligands, and new

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

He earned his PhD in Physics at the same university, focusing on in silico structural vaccinology and Now in a tenure-track position, his research spans the development of computational methods such as structure-based Scholar ResearchGate Bysky App : @ riccardocapelli.bsky.social Twitter X : @ ric_capelli Computational Structural

I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

A landmark Cell paper delivers the answer—mapping how conserved and variable sequence–structure elements “private” binding determinants ♦️ Highlights role of structured + unstructured regions ♦️ Includes a

signaling mechanisms employed by these atypical 7-transmembrane receptors, combining biochemical and structural begun studying GPCR signaling pathways that operate within the primary cilium, a tiny antenna-shaped structure Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure

Ray Stevens in 2013 solving several GPCR crystal structures, including that of the first serotonin receptor Bryan Roth where I established GPCR structural biology and learned the ins and outs of molecular pharmacology started my own lab at the Icahn School of Medicine at Mount Sinai in NYC, where I have been working on structure-function

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New

Current affiliation: Department of Structural Biology, Genentech, South San Francisco, CA, USA" About Kordon "I am a postdoctoral scholar in the Araç Lab at The University of Chicago, studying the structure Utilizing synthetic antibody fragments, I aim to understand better the structural basis of the aGPCRs University of Copenhagen, Copenhagen, Denmark. (2) Department of Psychiatry and Molecular Pharmacology and Therapeutics Columbia University Vagelos College of Physicians and Surgeons, New York, USA; Division of Molecular Therapeutics

Martin Audet Structural biologist, pharmacologist, and a professor of pharmacology at Université de Sherbrooke the AudetLab located at the Institute of Pharmacology of Sherbrooke and is an emerging leader in the structural

Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies

technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.

overcome these obstacles by producing high-quality antibodies that more accurately mimic natural protein structures This approach contrasts with other antigen forms like peptides or DNA, which face limitations in structural

Communications, which she joined in April 2020, following three years on the editorial teams of Nature Structural Katarzyna handles submissions in structural biology, biophysics and biochemistry, with a particular focus

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

With hundreds of subtypes and very few known ligands, the structure–function relationships remain largely .” – Alessandro Nicoli He explained how AlphaFold’s predictions, surprisingly close to experimental structures More structures, better tools, and deeper insights into the elegant, complex world of GPCRs. By bridging structural prediction, molecular dynamics, and ligand discovery, his work not only deciphers Alessandro PhD work aims to fill these gaps by leveraging computational structure-based tools and develop

Presentations Health and Disease, Metabolism, Nervous System, Proteomics and Transcriptomics, Receptor Structure The shorter BAI1 isoforms lack most of the N-terminus and are very close in structure to the truncated graduate student, he worked in the EuGEF Research Group to identify novel prognostic biomarkers and therapeutic significant tissue-specific mRNA processing that results in holoreceptors with unique and variable N-terminal structures Clearly, a new, less toxic therapeutic is needed.

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

But in the quiet hours, he found himself drawn to the structures, to the models, to figuring out why Today, Jens is a Professor of Computational Biochemistry at Uppsala University , where his lab uses structure-based

Brain’s work there primarily focused on structure prediction of GPCRs from sparse experimental data. of California in San Francisco to continue his training as a postdoctoral researcher where he used structural

His Ph.D. work has been focused on understanding the structure and activation of Class D fungal GPCRs developed novel tools and methodologies to study fungal GPCRs which allowed the determination of the first structures

biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

One of the best tools to study therapeutic targets are fluorescent ligands, which are very useful in Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic